CM
RIGL icon

Crestline Management’s Rigel Pharmaceuticals RIGL Stock Holding History

Crestline Management’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-66,492
Closed -$1.88M – 218
2018
Q2 		$1.88M Buy
66,492
+35,453
+114% +$1.26M 0.2% 148
2018
Q1 		$1.1M Sell
31,039
-7,381
-19% -$295K 0.14% 139
2017
Q4 		$1.49M Buy
38,420
+5,516
+17% +$210K 0.15% 60
2017
Q3 		$836K Sell
32,904
-14,265
-30% -$347K 0.12% 108
2017
Q2 		$1.29M Buy
+47,169
New +$1.29M 0.17% 67

Other funds holding RIGL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
TA
Tamarack Advisers Carlsbad, California $2.12M AUM 58.09% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Crestline Management's RIGL Position: Q3 2018 in Review

Crestline Management sold out of Rigel Pharmaceuticals (RIGL) in Q3 2018, closing a stake of 66,492 shares — an estimated $1.88M sold.

Crestline Management first reported a position in RIGL in Q2 2017 and held it in 5 quarters. The position peaked at $1.88M in Q2 2018. 135 funds tracked by Wall St. Rank hold RIGL as of Q3 2018.

  • Crestline Management reported no remaining Rigel Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • Crestline Management sold 66,492 Rigel Pharmaceuticals shares in Q3 2018, an estimated $1.88M.
  • Crestline Management first reported a position in Rigel Pharmaceuticals in Q2 2017 and held it in 5 quarters.
  • Crestline Management's Rigel Pharmaceuticals position peaked at $1.88M in Q2 2018.
  • 135 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q3 2018.

Based on Crestline Management's 13F filing for Q3 2018, filed 14 Nov 2018.